Myeloproliferative Neoplasms: Ten Years After JAK2-V617F
How does JAK2V617F contribute to pathogenesis of myeloproliferative neoplasms?
JAK2V617F突变导致骨髓增殖性肿瘤的机制
Therapy for myeloproliferative neoplasms: When, which agent, and how?
骨髓增殖性肿瘤治疗:治疗时机、治疗药物、治疗方案
The evolving genomic landscape of myeloproliferative neoplasms
骨髓增殖性肿瘤的基因研究进展
中国医学科学院血液病医院
肖志坚 教授